SynthesisFrontiers in oncology2024

Ponatinib vs. asciminib in post-second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison.

Valentin Garcia-Gutierrez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.